

There are a number of public health advocates who appear to consider electronic cigarettes (e-cigarettes) primarily as a threat to public health, and bodies such as the British Medical Association (BMA) and the World Health Organization (WHO) are warning smokers about their potential dangers.<sup>1</sup> This editorial takes a close look at the evidence.

### WHAT ARE E-CIGARETTES?

E-cigarettes are devices designed to give much of the experience of smoking and usually contain a certain amount of nicotine without exposing the user to the highly carcinogenic tar and harmful carbon monoxide gas that cigarettes deliver.<sup>2</sup> Many of them look broadly similar to cigarettes but are often larger and sport different colours; some look very different from cigarettes. Some have a tip that glows red, blue, or green when the user sucks on them. They contain a battery-powered heating element that is activated either manually or automatically when the user sucks on the end. This element heats a liquid mostly made up of propylene glycol or glycerol, usually with some nicotine and flavourings. The resulting vapour is inhaled and delivers varying amounts of nicotine, typically less than from smoking, depending on the device and experience of the user. Some of the vapour is exhaled as a visible mist.

Given that smokers smoke primarily for the nicotine but die primarily from the tar,<sup>3</sup> one might imagine that e-cigarettes would be welcomed as a means to prevent much of the death and suffering caused by cigarettes. For every million smokers who switched to an e-cigarette we could expect a reduction of more than 6000 premature deaths in the UK each year, even in the event that e-cigarette use carries a significant risk of fatal diseases, and users were to continue to use them indefinitely.

### SAFETY OF E-CIGARETTES

This raises the question as to why some in the public health community are so vociferous in their opposition to them. One concern is over safety. Given how long it took to discover the link between smoking and lung cancer when the risks were so great, we have to accept that it will probably be more than 30 years before we would have a chance of being able to use epidemiology to

quantify risks from e-cigarette use. In fact we may never be able to do so because we are chasing a moving target in terms of the products and their development.

This means that we must make judgements based on the toxicology of the vapour. Despite alarmist commentaries, studies on the toxicology of the vapour tell us that, while propylene glycol is an irritant and some toxins are present in measurable quantities, the concentrations are in fact very low.<sup>4</sup> Some reviews have bizarrely concluded that we do not know whether e-cigarette use is safer than smoking,<sup>5</sup> ignoring the fact that the vapour contains nothing like the concentrations of carcinogens and toxins as cigarette smoke.<sup>6,7</sup> In fact, toxin concentrations are almost all well below 1/20th that of cigarette smoke.

### EFFECT OF E-CIGARETTES ON SMOKING PREVALENCE

The second concern is that widespread use of e-cigarettes may 're-normalise' smoking, leading to an increase in smoking prevalence, or at least a slowing down of the rate of decline. Yet, in England, where the 'Smoking Toolkit Study' surveys the adult population every month, the rise in prevalence of e-cigarette use has been accompanied by an increase in smoking cessation rates and a continued fall in smoking prevalence.<sup>8,9</sup> The proportion of those aged 16–25 years who have ever smoked regularly has stayed constant at 30% over the period when e-cigarette use has increased.<sup>8</sup>

### E-CIGARETTES AND SMOKING CESSATION

The third concern is that there is only limited scientific evidence that e-cigarettes can help smokers to stop smoking. Two randomised controlled trials (RCTs) of now obsolete products that delivered little nicotine found those products to yield success rates broadly similar to licensed

nicotine products.<sup>10,11</sup> More trials of newer products are needed but these will only give us part of the answer. The number and variety of products, the rate of development, the time taken to conduct these trials, and the difficulty in generalising to people who are not willing to be randomised mean that we will have to supplement randomised trials with other kinds of study.

A review of surveys suggested that e-cigarette use by smokers might hinder quitting. However, the studies reviewed could not address the question satisfactorily because they failed to address differences in important factors such as nicotine dependence among those using e-cigarettes versus other smokers, and/or did not address whether the e-cigarettes were used as part of a quit attempt.<sup>6</sup> A recent study has addressed these deficiencies.<sup>9</sup> It used a survey methodology that had previously confirmed RCT findings that behavioural support and licensed nicotine products and varenicline obtained on prescription all improve smokers' chances of stopping, while confirming findings from other studies that licensed nicotine products when bought over the counter may not improve the chances of stopping.<sup>12,13</sup> The latest study, involving almost 6000 respondents, found that use of an e-cigarette in the most recent quit attempt was associated with a 60% increase in the odds of still being abstinent compared with using no aid and with using a licensed nicotine product bought over the counter.<sup>14</sup> This difference persisted after adjusting statistically for a wide range of potential confounding variables. This is just one correlational study but it is an important piece of the jigsaw.

### E-CIGARETTES AS A GATEWAY TO SMOKING

The fourth concern is that e-cigarettes may act as a gateway into smoking. The gateway hypothesis has been widely debated in relation to 'soft' and 'hard' drugs and it has

---

*"For every million smokers who switched to an e-cigarette we could expect a reduction of more than 6000 premature deaths in the UK each year ..."*

---

“... it is important that interpretation of the evidence and communication with policy makers and the public is not distorted by a priori judgements.”

been recognised that simply counting the numbers of people who try a ‘soft’ drug and go on to use a ‘hard’ drug does not address the question.<sup>14</sup> The reason is obvious: the association could easily be due to a pre-existing disposition on the part of the people concerned. To date, studies that have been claimed as addressing the gateway issue in relation to e-cigarettes have not in fact done so.<sup>1</sup> Moreover, warnings about a rapid rise in e-cigarette use among the young have been based on the proportion of young people who report ever having tried an e-cigarette, not the proportion of current users.<sup>15</sup> In England, the proportion of current users in people who have not smoked regularly remains extremely small at 0.2%.<sup>8</sup>

### THE NEED FOR OBJECTIVITY

This brings us back to the question as to why some individuals and bodies involved in public health are so opposed to e-cigarettes. It may be a concern over how things might turn out in the future given commercial incentives, puritanical ethics, distaste for any industry profiting from a psychoactive drug, inappropriate application of a medical rather than a public

### ADDRESS FOR CORRESPONDENCE

#### Robert West

University College London, Department of Epidemiology and Public Health, 2–16 Torrington Place, London WC1E 6BT, UK.

E-mail: robert.west@ucl.ac.uk

health model, or even just a gut feeling that e-cigarettes are bad. Whatever the reasons, it is important that interpretation of the evidence and communication with policy makers and the public is not distorted by a priori judgements.<sup>16</sup>

#### Robert West,

Professor of Health Psychology, Department of Epidemiology and Public Health, University College London, London.

#### Jamie Brown,

Post-doctoral research fellow, Department of Epidemiology and Public Health and Department of Clinical Educational and Health Psychology, University College London, London.

#### Provenance

Commissioned; not externally peer reviewed.

DOI: 10.3399/bjgp14X681253

### REFERENCES

1. World Health Organization. Regulatory scope. Tobacco product regulation. *WHO Drug Information* 2010; **24(1)**: 30–32.
2. Goniewicz ML, Hajek P, McRobbie H. Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. *Addiction* 2014; **109(3)**: 500–507.
3. Russell MA. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. *BMJ* 1976; **1(6023)**: 1430–1433.
4. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control* 2014; **23(2)**: 133–139.
5. Callahan-Lyon P. Electronic cigarettes: human health effects. *Tob Control* 2014; **23(Suppl 2)**: ii36–ii40.
6. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. *Circulation* 2014; **129(19)**: 1972–1986.
7. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. *Ther Adv Drug Safety* 2014; **5(2)**: 67–86.
8. West R, Brown J, Beard E. *Trends in electronic cigarette use in England*. STS140122. 2014. [www.smokinginengland.info/latest-statistics/](http://www.smokinginengland.info/latest-statistics/) [accessed 4 Aug 2014].
9. Brown J, Beard E, Kotz D, et al. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study. *Addiction* 2014; **109(9)**: 1531–1540.
10. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. *Lancet* 2013; **382(9905)**: 1629–1637.
11. Caponnetto P, Campagna D, Cibella F, et al. Efficacy and Safety of an eElectronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. *PLoS One* 2013; **8(6)**: e66317.
12. Kotz D, Brown J, West R. Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. *Psychopharmacology* 2014; **231(1)**: 37–42.
13. Kotz D, Brown J, West R. ‘Real-world’ effectiveness of smoking cessation treatments: a population study. *Addiction* 2014; **109(3)**: 491–499.
14. Degenhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use ‘gateway’ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. *Drug Alcohol Depend* 2010; **108(1–2)**: 84–97.
15. Durmowicz EL. The impact of electronic cigarettes on the paediatric population. *Tob Control* 2014; **23 (Suppl 2)**: ii41–ii46.
16. Hitchman SC, McNeill A, Brose LS. Electronic cigarettes: time for an accurate and evidence-based debate. *Addiction* 2014; **109(6)**: 867–868.